Jan 07, 2019
Biohaven Announces Acceptance Of Investigational New Drug (IND) Filing For Rimegepant In China
Dec 10, 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Dec 03, 2018
Biohaven Delivers Positive Phase 3 Results with Rimegepant Zydis® Orally Dissolving Tablet (ODT): Rapid and Lasting Benefit for the Acute Treatment of Migraine
Nov 28, 2018
Biohaven Announces Formation Of BioShin, A Wholly Owned Asia-Pacific Subsidiary
Nov 26, 2018
Biohaven Announces FDA Acceptance of 505(b)(2) NDA Filing for BHV-0223, a Novel Sublingual Delivery Form of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Nov 20, 2018
Biohaven Pharmaceuticals to Host Inaugural Research & Development Day on November 26, 2018
Nov 15, 2018
Biohaven Enrolls First Patient In Phase 3 Preventive Treatment Of Migraine Trial With Its Oral CGRP Receptor Antagonist Rimegepant
Nov 14, 2018
Biohaven Pharmaceuticals Reports Third Quarter 2018 Financial And Recent Business Results
Oct 22, 2018
Biohaven Receives Authorization to Proceed from FDA and Doses First Subject with BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist
Sep 12, 2018
Biohaven Announces Submission of IND for BHV-3500, Third-Generation, Small Molecule CGRP-Receptor Antagonist for the Treatment of Migraine
Sep 12, 2018
Biohaven Appoints Bob Repella to Board of Directors
Sep 06, 2018
Biohaven Presents at Migraine Trust International Symposium and Highlights Positive Results from Study 301 and Study 302 of Rimegepant, an Oral CGRP Receptor Antagonist, in the Acute Treatment of Migraine
Sep 05, 2018
Biohaven Licenses Novel Myeloperoxidase Inhibitor From AstraZeneca: Potential First-In-Class Treatment For Multiple System Atrophy
Aug 16, 2018
Biohaven Reports Positive Results From Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety
Aug 14, 2018
Biohaven Pharmaceuticals Reports Second Quarter 2018 Financial And Recent Business Results
Aug 01, 2018
First Patient Enrolled In Biohaven's Phase 2/3 Mild-To-Moderate Alzheimer's Clinical Trial
Jul 24, 2018
Biohaven Receives FDA May Proceed Letter And Initiates Phase 2/3 Clinical Trial Of Trigriluzole (BHV-4157) In Alzheimer's Disease
Jun 28, 2018
Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
Jun 13, 2018
Biohaven CEO Vlad Coric Named Ernst & Young Entrepreneur Of The Year 2018 Award Winner in New York Region
Jun 05, 2018
Biohaven to Present Key and Expanded Data from Phase 3 Clinical Trials of Rimegepant, its Oral CGRP Receptor Antagonist, During Four Late-Breaking Sessions at American Headache Society (AHS) Annual Scientific Meeting 2018